The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Tumor-targeted Delivery of siRNA by Self-assembled Nanoparticles
Open accessAbstract
We have developed a self-assembled nanoparticle (NP) that efficiently delivers small interfering RNA (siRNA) to the tumor by intravenous (IV) administration. The NP was obtained by mixing carrier DNA, siRNA, protamine, and lipids, followed by post-modification with polyethylene glycol and a ligand, anisamide. Four hours after IV injection of the formulation into a xenograft model, 70-80% of injected siRNA/g accumulated in the tumor, approximately 10% was detected in the liver and approximately 20% recovered in the lung. Confocal microscopy showed that fluorescent-labeled siRNA was efficiently delivered into the cytoplasm of the sigma receptor expressing NCI-H460 xenograft tumor by the targeted NPs, whereas free siRNA and non-targeted NPs showed little uptake. Three daily injections (1.2 mg/kg) of siRNA formulated in the targeted NPs silenced the epidermal growth factor receptor (EGFR) in the tumor and induced approximately 15% tumor cell apoptosis. Forty percent tumor growth inhibition was achieved by treatment with targeted NPs, while complete inhibition lasted for 1 week when combined with cisplatin. The serum level of liver enzymes and body weight monitoring during the treatment indicated a low level of toxicity of the formulation. The carrier itself also showed little immunotoxicity (IMT).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yang, R., Yang, X., Zhang, Z., Zhang, Y., Wang, S., Cai, Z., Jia, Y., Ma, Y., Zheng, C., Lu, Y., et al. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302808 · Cited by 98
Self-citationRetractedNanoparticle and targeted systems for cancer therapy
Brannon-Peppas, L., & Blanchette, J. O. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.02.014 · Cited by 2,334
Nicholson, R. I., Gee, J. M. W., & Harper, M. E. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,143
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,232
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,002
Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 901
Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review
Braet, F., & Wisse, E. (2002) · Comparative Hepatology · doi:10.1186/1476-5926-1-1 · Cited by 753
In vivo imaging of siRNA delivery and silencing in tumors
Medarova, Z., Pham, W., Farrar, C., Petkova, V., & Moore, A. (2007) · Nature Medicine · doi:10.1038/nm1486 · Cited by 697
Cited by
Controlled drug delivery vehicles for cancer treatment and their performance
Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0004-3 · Cited by 2,167
Pharmacokinetics and Biodistribution of Nanoparticles
Li, S.-D., & Huang, L. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800049w · Cited by 1,568
Self-citationTargeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery
Lee, H., Lytton-Jean, A. K. R., Chen, Y., Love, K. T., Park, A. I., Karagiannis, E. D., Sehgal, A., Querbes, W., Zurenko, C. S., Jayaraman, M., et al. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.73 · Cited by 1,169
Self-citationAshley, C. E., Carnes, E. C., Phillips, G. K., Padilla, D., Durfee, P. N., Brown, P. A., Hanna, T. N., Liu, J., Phillips, B., Carter, M. B., et al. (2011) · Nature Materials · doi:10.1038/nmat2992 · Cited by 1,024
Ernsting, M. J., Murakami, M., Roy, A., & Li, S.-D. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.09.013 · Cited by 1,012
Self-citationAssessment of the Evolution of Cancer Treatment Therapies
Arruebo, M., Vilaboa, N., Sáez-Gutierrez, B., Lambea, J., Tres, A., Valladares, M., & González-Fernández, Á. (2011) · Cancers · doi:10.3390/cancers3033279 · Cited by 931
Nanomaterials: Applications in Cancer Imaging and Therapy
Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 907
Delivery of siRNA Therapeutics: Barriers and Carriers
Wang, J., Lu, Z., Wientjes, M. G., & Au, J. L.-S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9210-4 · Cited by 798
siRNA delivery systems for cancer treatment
Oh, Y.-K., & Park, T. G. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.018 · Cited by 645
Kraft, J. C., Freeling, J. P., Wang, Z., & Ho, R. J. Y. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23773 · Cited by 606
Recent Advances in Nonviral Vectors for Gene Delivery
Guo, X., & Huang, L. (2012) · Accounts of Chemical Research · doi:10.1021/ar200151m · Cited by 584
Self-citationStealth nanoparticles: High density but sheddable PEG is a key for tumor targeting
Li, S.-D., & Huang, L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.016 · Cited by 562
Self-citationNanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.136 · Cited by 515
Self-citationThe Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Molecular Mechanisms and Biological Functions of siRNA
Department of Biology, D. B., Dana, H., Chalbatani, G. M., Mahmoodzadeh, H., Gharagouzlo, E., Cancer Research Center, C. I. O. I., Karimloo, R., Department of Medicine, Z. M. S., Rezaiean, O., Moradzadeh, A., et al. (2017) · International Journal of Biomedical Science · doi:10.59566/ijbs.2017.13048 · Cited by 505
Nanoparticles evading the reticuloendothelial system: Role of the supported bilayer
Li, S.-D., & Huang, L. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2009.06.022 · Cited by 486
Self-citationBiodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery
Li, J., Chen, Y.-C., Tseng, Y.-C., Mozumdar, S., & Huang, L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.008 · Cited by 470
Self-citationMore Effective Nanomedicines through Particle Design
Wang, J., Byrne, J. D., Napier, M. E., & DeSimone, J. M. (2011) · Small · doi:10.1002/smll.201100442 · Cited by 466
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Self-citationMechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Juliano, R., Alam, M. R., Dixit, V., & Kang, H. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn342 · Cited by 429
Sun, T.-M., Du, J.-Z., Yao, Y.-D., Mao, C.-Q., Dou, S., Huang, S.-Y., Zhang, P.-Z., Leong, K. W., Song, E.-W., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn103349h · Cited by 406
Materials for non-viral intracellular delivery of messenger RNA therapeutics
Kauffman, K. J., Webber, M. J., & Anderson, D. G. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.032 · Cited by 395
Gandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
In Vivo Gene Delivery by Nonviral Vectors: Overcoming Hurdles?
Zhang, Y., Satterlee, A., & Huang, L. (2012) · Molecular Therapy · doi:10.1038/mt.2012.79 · Cited by 349
Self-citationTherapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriers
Scholz, C., & Wagner, E. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.014 · Cited by 333
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
Li, J., Yang, Y., & Huang, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.020 · Cited by 306
Self-citationAleku, M., Schulz, P., Keil, O., Santel, A., Schaeper, U., Dieckhoff, B., Janke, O., Endruschat, J., Durieux, B., Röder, N., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2428 · Cited by 293
Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics
Lorenzer, C., Dirin, M., Winkler, A.-M., Baumann, V., & Winkler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.003 · Cited by 284
“Grafted to the surface of lipid/protamine siRNA nanoparticles, anisamide afforded intracellular uptake of the siRNA cargo [144].”
BackgroundCancer‐Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery
Vaughan, H. J., Green, J. J., & Tzeng, S. Y. (2020) · Advanced Materials · doi:10.1002/adma.201901081 · Cited by 255
Phosphorescent Nanoscale Coordination Polymers as Contrast Agents for Optical Imaging
Liu, D., Huxford, R. C., & Lin, W. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201008277 · Cited by 254
Shen, H., Hong, S., Prud’homme, R. K., & Liu, Y. (2011) · Journal of Nanoparticle Research · doi:10.1007/s11051-011-0354-7 · Cited by 120
Core-Shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery
Gao, L.-Y., Liu, X.-Y., Chen, C.-J., Wang, J.-C., Feng, Q., Yu, M.-Z., Ma, X.-F., Pei, X.-W., Niu, Y.-J., Qiu, C., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.046 · Cited by 114
Metadata
- Authors
- Li, S.-D., Chen, Y.-C., Hackett, M. J., & Huang, L.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-01
- Volume
- 16
- Issue
- 1
- Pages
- 163-169
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1989611595
- Cited by
- 333
- References
- 43
- FWCI
- 7.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.